Navigation Links
Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
Date:1/24/2011

s our goal of helping patients who are suffering from this disease." 

The NDA is supported by data from the two largest comparative Phase 3 clinical trials ever conducted against vancomycin in CDI. The two fidaxomicin Phase 3 clinical studies were multi-center, randomized, double-blind trials, which enrolled a total of 1,164 adult patients. Patients with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin® (125 mg q6h), the only FDA approved product for the treatment of CDI. In both of these studies, fidaxomicin met the primary endpoint of non-inferiority of clinical cure compared to Vancocin. Importantly, in both trials fidaxomicin was statistically superior to Vancocin in reducing recurrences of CDI and in global cure rate.

About Clostridium difficile Infection (CDI)Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Seventy-one percent of Americans ... OxyContin is a serious public health and safety issue in ... from a survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication ... progress with this very serious health situation facing our country," ...
(Date:8/21/2014)... August 21, 2014 BreedIT ... Ltd., the exclusive worldwide license holder and distributor ... breeders and researchers, today is pleased to announce ... with Seach Ltd, a leading Israeli medical Cannabis ... and develop new breeds of medical Cannabis to ...
(Date:8/21/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... dental, animal health and medical practitioners, announced today that the ... , September 4, 2014 – Baird 2014 Healthcare Conference ... ET , September 8, 2014 – Morgan ... , NY at 1:25 p.m. ET Henry Schein,s ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4Henry Schein To Present At Two Investor Conferences In September 2
... Australia, May 4 /PRNewswire-Asia-FirstCall/ -- Pharmaceutical,company Pharmaxis (ASX: PXS; ... positive,results of its recently completed international Phase III trial ... represents one of,the largest clinical trials conducted in cystic ... of the trial was to assess whether Bronchitol,improves lung ...
... Va., May 1 C. Larry Pope, President and ... SFD ), sent the following update to all ... at its joint venture operation in Veracruz:To Our Employees:The ... on a minute-to-minute basis, and while we would like ...
Cached Medicine Technology:Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 2Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 3Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 4Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial 5Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 Cardiomyopathy ... the function of the myocardium (the heart muscle) ... common symptoms are dyspnea (breathlessness) and peripheral edema ... often at risk of dangerous forms of irregular ... common form of cardiomyopathy is dilated cardiomyopathy. , ...
(Date:8/23/2014)... 2014 Peripheral intervention surgeries are part ... etc, thereby addressing the root cause of peripheral artery ... to the other part of the arteries where the ... procedures require the use of a catheter, (which is ... these catheters are inserted through a thin cut in ...
(Date:8/23/2014)... New York (PRWEB) August 23, 2014 ... ) filed on behalf of individuals who ... Conserve hip replacement line continue to move forward ... Georgia, Bernstein Liebhard LLP reports. According to an ... a bellwether trial program that would allow the ...
(Date:8/23/2014)... 23, 2014 Professional kitchen employees, prospective ... aid in preparing for Food Safety Certification exams thanks ... by Dynamic Path. , Dynamic Path announced the release ... more than 200 review questions for culinary industry students ... to cover requirements of the ServSafe® Food Safety Certification, ...
(Date:8/23/2014)... Teen drug and alcohol abuse is a major ... NC. Substance abuse can happen to people of all ... alcohol dependency in higher numbers than ever before. ... but don’t know where to find professional youth rehab. ... challenge because most treatment options are designed for adults. ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
... recently diagnosed with diabetes and hypertension have time to ... pressure without medications, but not too much time. ... up to a year were smalla two-day reduction in ... Chicago researchers published online for the Journal of ...
... the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial ... control group of men undergoing usual care, according to a ... the National Cancer Institute. The Prostate, ... multi-center, two-arm trial, which began enrollment in November 1993 with ...
... of imaging services received by patients in a hospital, in-patient ... the Journal of the American College of Radiology . ... of the population, were without health insurance for some or ... preventive care, delays in diagnosis and unnecessary deaths. ...
... FRIDAY, Jan. 6 (HealthDay News) -- Air pollution may increase ... in black American women, a new study suggests. Previous ... acute cardiovascular events such as stroke and heart attack, but ... of chronic diseases such as diabetes and high blood pressure ...
... , FRIDAY, Jan. 6 (HealthDay News) -- If the current ... has left you searching for something else for your child ... the effects of these medications can vary widely. ... much of the drug is absorbed into the bloodstream], and ...
... documents shows that Philip Morris USA manipulated data on ... actual toxicity levels and increasing the risk of heart, ... information can,t be taken at face value, the researchers ... of additives, including menthol, should be eliminated from cigarettes ...
Cached Medicine News:Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 2Health News:For those with diabetes, controlling blood pressure is crucial, but not urgent 3Health News:Study shows no evidence of a mortality benefit to PSA screening 2Health News:Smog Tied to Raised Risk of Chronic Illness in Black Women 2Health News:ADHD Drug Shortage Pushes Parents to Seek Substitutes 2Health News:ADHD Drug Shortage Pushes Parents to Seek Substitutes 3Health News:Tobacco company misrepresented danger from cigarettes 2
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
... Rapid Immunoassay: Uni-Gold Recombigen HIV is a single ... to HIV-1 in plasma, serum and whole blood ... in point of care settings as an aid ... is suitable for use in appropriate multi-test algorithms ...
... The advanced performance ... have been applied to ... Reduction Implants) Upper Extremity ... rigidity combine to provide ...
... CHS System takes the time proven technology ... ,The VHS® Supracondylar Cable Plate is designed ... femur fractures including periprosthetic fractures. The combination ... angle of the barrel and the plate ...
Medicine Products: